Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiroshi Okamoto has a total of 226 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    3‐Indoxyl Sulfate and O ‐Acetylcarnitine Are Potential Novel Biomarkers for Early Diagnosis of Esophageal Cancer

    by Kenji Hamada, Yohei Ozawa, Hiroshi Okamoto, Shinji Fukuda, Tomoyoshi Soga, Takaaki Abe, Hozumi Motohashi, Shohei Murakami, Takashi Kamei

    Esophageal cancer is the seventh most common cancer worldwide, and early detection is crucial for improving long‐term survival. However, reliable noninvasive biomarkers for early‐stage disease remain limited. In this study, we aimed to identify novel biomarkers for early‐stage esophageal cancer through comprehensive metabolomic analyses of plasma and urine samples from patients and healthy individuals. Metabolomic profiling revealed that 3‐indoxyl sulfate (3‐IS) was consistently elevated in both plasma and urine of esophageal cancer patients. As esophageal cancer cells do not directly produce 3‐IS, its elevation may reflect cancer‐associated systemic metabolic alterations. O ‐acetylcarnitine ( O ‐AC) was identified as the most significantly increased metabolite in plasma, and in vitro analyses suggested a possible association with tumor‐related metabolic changes. Receiver operating characteristic analyses (ROC) demonstrated that the combined plasma and urinary 3‐IS model achieved an area under the curve (AUC) of 0.863 in Stage I/II disease, whereas plasma O ‐AC achieved an AUC of 0.902. Bootstrap resampling provided internal validation; however, the discovery and evaluation were performed within the same single‐center cohort. These results suggest that 3‐IS and O ‐AC are promising candidate biomarkers that distinguish patients with esophageal cancer from healthy individuals, but further validation of their disease specificity and diagnostic performance is required in independent multicenter cohorts including clinically relevant disease‐control groups.

  • Open Access

    The Evolution of Neoadjuvant Treatment for Resectable Esophageal Squamous Cell Carcinoma: Past Achievements, Current Standards, and Future Perspectives

    by Naoto Ujiie, Yusuke Taniyama, Chiaki Sato, Hiroshi Okamoto, Yohei Ozawa, Hirotaka Ishida, Michiaki Unno, Takashi Kamei

    Neoadjuvant treatment has become an integral component of multidisciplinary management for resectable esophageal squamous cell carcinoma (ESCC). Over recent decades, treatment has evolved from surgery alone to postoperative chemotherapy, neoadjuvant chemotherapy, intensified systemic therapy, neoadjuvant chemoradiotherapy, and, more recently, the incorporation of immune checkpoint inhibitors into curative-intent treatment. This evolution has been driven by persistent challenges including systemic recurrence, locoregional failure, treatment-related toxicity, and heterogeneous treatment response. This review traces the evolution of neoadjuvant treatment for resectable ESCC through landmark clinical trials that have shaped current practice. We discuss the transition from postoperative to neoadjuvant chemotherapy, the development of intensified chemotherapy and neoadjuvant chemoradiotherapy, and the emergence of immunotherapy, distinguishing the established role of adjuvant nivolumab from the emerging role of neoadjuvant immunochemotherapy. We then examine the unresolved relative roles of these strategies and the challenges in treatment selection. Finally, we discuss future directions centered on accurate response assessment, circulating tumor DNA-based molecular residual disease assessment, and response-adapted treatment, with particular emphasis on organ-preserving strategies after a clinical complete response. Although active surveillance has emerged as a potential alternative to immediate surgery in carefully selected patients, accurate identification of residual disease and appropriate surveillance remain essential. Future advances may therefore shift the focus from treatment intensification alone toward response-adapted strategies that can maintain oncological safety while potentially enabling organ preservation.

  • Harvest of a pedicled omental flap preserving the right gastroepiploic artery for gastric conduit reconstruction in multistage surgery for aortoesophageal fistula

    by Hiroshi Okamoto, Yusuke Taniyama, Chiaki Sato, Yohei Ozawa, Hirotaka Ishida, Takashi Kamei

    Aortoesophageal fistula is a rare but highly fatal condition. Thoracic endovascular aortic repair has led to improved early outcomes. However, subsequent aortic replacement, esophagectomy, and gastrointestinal reconstruction are required to achieve long-term survival. Conventional pedicled flaps using both gastroepiploic arteries can prevent gastric conduit reconstruction, requiring small or large intestinal substitutes associated with greater surgical invasiveness. We developed the pedicled omental flap technique preserving the right gastroepiploic artery, which enabled simultaneous gastric conduit preparation and omental harvest in a multistage surgery. After a specific interval following esophagectomy, the omental flap was mobilized while preserving right gastroepiploic perfusion, and a gastric conduit was created. Both were evaluated via indocyanine green imaging. The omental flap was delivered into the thoracic cavity for later graft coverage. Meanwhile, the gastric conduit was left in situ for delayed reconstruction. This method reduced invasiveness and facilitated staged treatment of aortoesophageal fistula with improved surgical flexibility.

  • Open Access

    Rapid detection of Fusobacterium nucleatum in saliva using magnetic flux change

    by Shin Yabukami, Amane Ban, Toru Murayama, Kazuhiko Okita, Shunta Tohtake, Loi Tonthat, Yohei Ozawa, Seji Asamitsu, Hiroshi Okamoto, Takashi Kamei, et al.

    We have developed a low-cost, rapid, and highly sensitive antigen test for Fusobacterium Nucleatum that utilizes the antigen-antibody reaction between magnetic nanoparticles and biological materials (antigens), which changes the magnetic flux passing through the small pickup coil. The magnetic flux of the pickup coil decreased with increasing antigen concentration because the density of magnetic nanoparticles decreased with increasing antigen concentration. The driving coil was air-cooled to reduce thermal drift, and the size of the differential pickup coil was reduced to achieve a high signal-to-noise ratio in magnetic flux measurements. After the antigen-antibody reaction, the magnetic nanoparticles and antigens are agglutinated by magnetic force, reducing the influence of contaminants and allowing the concentration of Fusobacterium Nucleatum to be evaluated without a washing step. The method was validated using samples collected from 28 individuals. The results showed a strong correlation with qPCR analysis (correlation coefficient = 0.69, p < 0.0001), highlighting the accuracy and precision comparable to conventional qPCR systems. The proposed approach offers several advantages for bacterial detection: low cost, rapid evaluation, high sensitivity, and minimal interference from contaminants.


  • Open Access

    Noninvasive Breathomics for Developing Carbonyl Biomarkers in Esophageal Cancer

    by Kazuki Fusegawa, Yohei Ozawa, Seiryo Ogata, Hiroshi Okamoto, Tsuyoshi Takata, Masanobu Morita, Jun Yoshitake, Tomoaki Ida, Seji Asamitsu, Yusuke Taniyama, et al.

    Background Despite being the gold standard for esophageal cancer (EC) diagnosis, the invasiveness and cost limit the use of upper gastrointestinal endoscopy for primary screening. We evaluated the potential of aldehyde profiling in exhaled breath condensate (EBC), a noninvasively obtained biofluid, as an EC diagnostic biomarker. Methods EBC, plasma, or saliva samples were collected from 152 patients with EC and 63 healthy controls (HC); aldehyde concentrations in EBC and plasma were measured using liquid chromatography–tandem mass spectrometry. Saliva microbiota was analyzed by 16S rRNA sequencing, focusing on oral acetaldehyde-producing bacteria. Results Among eight different aldehydes measured using EBC samples, acetaldehyde and formaldehyde concentrations were significantly higher in patients with EC than in HC, with elevations observed in both early and advanced-stage disease. Plasma acetaldehyde and formaldehyde levels were also increased in patients with EC compared with that in HC. EBC acetaldehyde and formaldehyde were identified as diagnostic biomarkers (areas under the curve: 0.77/0.87, sensitivities: 78%/89%, specificities: 70%/79%). It remains unclear whether the salivary microbiota influence the acetaldehyde concentration in EBC. Conclusions Acetaldehyde and formaldehyde in EBC are potential diagnostic biomarkers for EC. EBC is a noninvasive sample useful for screening with potential utility for early detection of EC.

  • Open Access

    Prospective Survey of Postoperative Pain in Japan: A Multicenter, Observational Study

    by Masaki Kaibori, Kengo Yoshii, Tung Thanh Lai, Hideyuki Matsushima, Wataru Tatsuishi, Ryo Inada, Yasuhiro Matsugu, Koji Komeda, Mitsuhiro Asakuma, Keitaro Tanaka, et al.

    Background/Objectives: Postoperative analgesia is important for reducing biologically invasive reactions to surgery. In Japan, postoperative analgesia, including indices of analgesia, has not been adequately addressed. This study aimed to determine the relationship between postoperative pain and postoperative course and the importance of analgesia for early recovery. Methods: Patients who underwent any of seven surgical procedures in gastrointestinal, thoracic, and cardiac surgery were enrolled. The primary endpoint was a median Prince Henry Pain Scale score from postoperative days 1 to 3. Secondary endpoints were the quality of recovery on postoperative day 7 (Quality of Recovery-15 [QoR-15]) and the length of postoperative hospital stay. Results: Median postoperative pain levels among surgeries were 3 on day 1, 2 on days 2 and 3, 1 on day 7, and 1 at discharge. In both univariate and multivariate analyses, the use of postoperative epidural analgesia and intravenous patient-controlled analgesia (IV-PCA) were significant predictors of early postoperative pain. Only early postoperative pain was a significant predictor of QoR-15 score. Regular use of acetaminophen, early postoperative pain, no appetite, and postoperative complications were significant in affecting the length of postoperative hospital stay. In the comparison of early postoperative pain according to whether epidural analgesia and IV-PCA were used, the group that used both methods had the least pain. Conclusions: In Japan, early postoperative pain persists after major surgical procedures and affects postoperative quality of recovery and length of hospital stay. The use of epidural analgesia, IV-PCA, or both appeared to be effective in overcoming early postoperative pain, thereby enhancing early postoperative recovery.


  • Open Access

    Histopathological study of the localization/distribution of Fusobacterium nucleatum in esophageal cancer

    by Iku Sasaki‐Higashimoto, Fumiyoshi Fujishima, Hirotaka Ishida, Yusuke Taniyama, Yohei Ozawa, Tomohiro Nakamura, Naoki Nakaya, Chiaki Sato, Hiroshi Okamoto, Junichi Tsunokake, et al.

    Fusobacterium nucleatum is implicated in esophageal cancer; however, its distribution in esophageal cancer tissues remains unknown. This study aimed to clarify the presence and distribution of F. nucleatum in esophageal cancer tissues using fluorescence in situ hybridization (FISH). Tissues collected from 70 patients with esophageal squamous cell carcinoma were examined using FISH. Corresponding normal epithelium and metastatic lymph nodes were assessed. F. nucleatum was identified more frequently in esophageal cancer tissues than in the normal epithelium. F. nucleatum also showed significant correlation with factors associated with tumor progression, such as pT factor and tumor size. As tumor progression advanced, the area occupied by F. nucleatum gradually became larger. F. nucleatum positivity was observed around the deep edge of the tumor nest (border‐dense type) or identified diffusely in the tumor nest (diffuse distributed type). Furthermore, F. nucleatum was observed in metastatic lymph nodes, lesions of venous invasion, and walls of veins in normal epithelium. In conclusion, we visualized F. nucleatum using FISH and identified different distribution patterns of F. nucleatum, highlighting the spot density of its presence in tumor tissues. Recognizing this quantitative change is pivotal for establishing F. nucleatum as a reliable biomarker.


  • Open Access

    Prevention and Management of Recurrent Laryngeal Nerve Palsy in Minimally Invasive Esophagectomy: Current Status and Future Perspectives

    by Yusuke Taniyama, Hiroshi Okamoto, Chiaki Sato, Yohei Ozawa, Hirotaka Ishida, Michiaki Unno, Takashi Kamei

    Recurrent laryngeal nerve palsy remains a significant complication following minimally invasive esophagectomy for esophageal cancer. Despite advancements in surgical techniques and lymphadenectomy precision, the incidence of recurrent laryngeal nerve palsy has not been improved. Recurrent laryngeal nerve palsy predominantly affects the left side and may lead to unilateral or bilateral vocal cord paralysis, resulting in hoarseness, dysphagia, and an increased risk of aspiration pneumonia. While most cases of recurrent laryngeal nerve palsy are temporary and resolve within 6 to 12 months, some patients may experience permanent nerve dysfunction, severely impacting their quality of life. Prevention strategies, such as nerve integrity monitoring, robotic-assisted minimally invasive esophagectomy, and advanced dissection techniques, aim to minimize nerve injury, though their effectiveness varies. The management of recurrent laryngeal nerve palsy includes voice and swallowing rehabilitation, reinnervation techniques, and, in severe cases, surgical interventions such as thyroplasty and intracordal injection. As recurrent laryngeal nerve palsy can lead to significant postoperative respiratory complications, a multidisciplinary approach involving surgical precision, early detection, and comprehensive rehabilitation is crucial to improving patient outcomes and minimizing long-term morbidity in minimally invasive esophagectomy. This review article aims to inform esophageal surgeons and other clinicians about strategies for the prevention and management of recurrent laryngeal nerve palsy in esophagectomy.


  • Open Access

    Prevention and Management of Recurrent Laryngeal Nerve Palsy in Minimally Invasive Esophagectomy, Current Status and Future Perspectives

    by Yusuke Taniyama, Hiroshi Okamoto, Chiaki Sato, Yohei Ozawa, Hirotaka Ishida, Michiaki Unno, Takashi Kamei

    Recurrent laryngeal nerve palsy remains a significant complication following minimally invasive esophagectomy for esophageal cancer. Despite advancements in surgical techniques and lymphadenectomy precision, the incidence of recurrent laryngeal nerve palsy has not been improved. Recurrent laryngeal nerve palsy predominantly affects the left side and may lead to unilateral or bilateral vocal cord paralysis, resulting in hoarseness, dysphagia, and an increased risk of aspiration pneumonia. While most cases of recurrent laryngeal nerve palsy are temporary and resolve within 6 to 12 months, some patients may result in permanent nerve dysfunction, severely impacting patient quality of life. Prevention strategies, such as nerve integrity monitoring, robotic-assisted minimally invasive esophagectomy, and advanced dissection techniques, aim to minimize nerve injury, though their effectiveness varies. Management of recurrent laryngeal nerve palsy includes voice and swallowing rehabilitation, reinnervation techniques, and, in severe cases, surgical interventions such as thyroplasty and intracordal injection. As recurrent laryngeal nerve palsy can lead to significant postoperative respiratory complications, a multidisciplinary approach involving surgical precision, early detection, and comprehensive rehabilitation is crucial to improving patient outcomes and minimizing long-term morbidity in minimally invasive esophagectomy.

  • Open Access

    Perioperative Administration of Cystine and Theanine Suppresses Inflammation and Facilitates Early Rehabilitation and Recovery after Esophagectomy: A Randomized, Double-Blind, Controlled Clinical Trial

    by Hiroshi Okamoto, Yusuke Taniyama, Tadashi Sakurai, Gaku Kodama, Chiaki Sato, Toshiaki Fukutomi, Yohei Ozawa, Hirotaka Ishida, Ken Koseki, Takuro Yamauchi, et al.

    Oral administration of cystine and theanine (CT) increases glutathione levels to modulate the inflammatory response, which has yet to be sufficiently explored for patients’ recovery and early rehabilitation. We planned a randomized, double-blind, placebo-controlled trial to determine whether perioperative oral administration of CT promotes recovery after esophagectomy. Patients were randomized into either CT or placebo groups, who received preoperative and postoperative treatments for 4 and 13 days, respectively. The main outcome measures were triaxial accelerometer readings, inflammation indicators, a 6 min walk test (6MWT), and a quality of life questionnaire (QoR-40). The study involved 32 patients. Although the CT group (n = 16) showed better patient activity across the investigated period, there was no significant difference between the two groups. However, white blood cell count on postoperative days (POD) 2 and 10, neutrophil count (POD 2, 7, and 10), and C-reactive protein level (POD 13) in the CT group were significantly lower than in the placebo group. Furthermore, 6MWT on POD 7 and QoR-40 on POD 13 were significantly higher in the CT group than those in the placebo group. This study suggests that perioperative administration of CT may contribute to early recovery and rehabilitation after esophagectomy via suppression of inflammatory response.